The initial approval was for the treatment of patients with metastatic NSCLC whose tumours have specific EGFR mutations, specifically T790M mutations, and whose disease has progressed on or after EGFR TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.